News / Taiwan / cnyes
Adimmune August Revenue Grows 34% YoY
Health Technology · Biotechnology · cnyes · 2026-09-04
4142
Adimmune (4142) reported August revenue of NT$97.92 million, a 34.46% year-over-year increase, showing resilience compared to the biotech sector index.
What Happened
Revenue Overview: Adimmune (4142) reported August 2026 revenue of NT$97.92 million, reflecting a 34.46% year-over-year increase, though it experienced a 68.23% month-over-month decline.
Cumulative Results: The company's cumulative revenue for the first eight months of 2026 reached NT$555 million, representing a year-to-date growth of 12.56%.
Stock Performance: Trading at NT$17.55, the stock declined 1.68% over the past five days, which is significantly better than the 9.59% drop seen in the biotech sector index.
Business Operations: Adimmune specializes in the manufacturing and development of vaccines, serums, diagnostic reagents, and biological products, alongside import and export services.
Read original
Latest in Taiwan
Electronic Technology · economic_daily · 2026-10-25
Major Taiwanese tech companies, including MediaTek and Delta Electronics, are set to report earnings, with investors watching for signs of AI-driven profitability.
1590, 2301, 2303, 2308, 2337, 2379, 2409, 2454, 3035, 3081, 3718, 4919, 4966, 4968, 6176, 6202, 6510, 7769, 8215
Electronic Technology · economic_daily · 2026-10-25
Amidst recent market volatility, institutional investors are aggressively buying 13 stocks that show strong fundamentals, technicals, and institutional support.
Finance · economic_daily · 2026-10-25
As the Taiwan stock market undergoes a correction, domestic institutional investors are actively positioning in AI-related stocks, infrastructure leaders, and dividend-paying financial firms.
Electronic Technology · economic_daily · 2026-10-25
Connector manufacturer Hu Lane will acquire an 80% stake in Italy's LA PUNTA S.R.L. for 6.88 million euros to enter the high-end motorcycle and supercar supply chains.
6279